Immune-related pneumonitis: keep the six-week steroid taper

Design

Randomised non-inferiority trial

Population

106 patients with grade 1–2 immune checkpoint inhibitor pneumonitis

Primary outcome

Treatment success at 8 weeks

Effect

66.7% (3 weeks) vs 85.2% (6 weeks); difference −18.5 points, non-inferiority not shown

This Japanese randomised trial is the first to test steroid duration for pneumonitis caused by immune checkpoint inhibitors. It enrolled 106 patients with mild (grade 1–2) pneumonitis, median age 72, and randomised them to a three-week or the guideline six-week taper.

Treatment success at eight weeks, defined as room-air saturation of 90% or more without steroid escalation or extension, was 66.7% with three weeks and 85.2% with six (difference −18.5 points). The three-week regimen failed to show non-inferiority, and a predefined exploratory analysis favoured six weeks. Grade 3 or worse adverse events were more frequent with six weeks (24% vs 12%), but all were manageable. Quality of life and overall survival did not differ.

With more patients receiving checkpoint inhibitors, including in Indian oncology practice, pneumonitis is increasingly managed by chest physicians. This trial gives the six-week taper a randomised basis and argues against shortening it to spare steroid exposure.

• Use a six-week steroid taper for grade 1–2 immune checkpoint inhibitor pneumonitis.
• Do not shorten the taper to three weeks; treatment failure was more common.
• Monitor for steroid side effects, especially glucose, mood and infection, during the longer course.
• Consider prophylaxis against Pneumocystis according to local protocol for prolonged steroids.
• Coordinate with the oncologist on whether and when to resume immunotherapy.

Why it matters

The first randomised evidence on steroid duration confirms the current guideline rather than shortening it.

Don't overread it

The trial covered only mild (grade 1–2) pneumonitis, not severe cases.

The statistics, in plain English

Non-inferiority asks whether the shorter course is not meaningfully worse. Here it was 18.5 percentage points worse, so it failed that test. The trial used an 80% confidence interval, which is narrower than the usual 95%; the exploratory superiority result should be read with that in mind.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.